Abstract
Coronary atherosclerotic heart disease is a serious threat to human health. The results of the Canakinumab Anti-Inflammatory Thrombosis Outcome Study published in 2017 put an end to the perennial debate about the anti-inflammatory treatment of coronary atherosclerotic heart disease. In addition to interleukin 1β monoclonal antibody, interleukin 6 receptor antagonists and colchicine have also shown exciting results in clinical trials within the last 3 years. However, behind these successes, questions remain that need to be addressed. In this review, we summarize the successes and existing doubts of interleukin 1β antibodies, interleukin 6 receptor antagonists, and colchicine in the anti-inflammatory treatment of coronary atherosclerotic heart disease.
Highlights
such as canakinumab have confirmed the inflammatory theory of coronary heart disease
such as colchicine have demonstrated the possibility of rapid clinical use
tocilizumab has an effect on lipid levels
Summary
Effect of a single dose of Phase II, Patients with NSTEMI the interleukin-6 receptor two-center, double-blind, antagonist tocilizumab on placebo-controlled trial inflammation and troponin. Patients with first-time STEMI 199 randomized, presenting within 6 h of the double blind, placebo-controlled onset of chest pain trial. Phase II, double-blinded, Patients with NSTE-ACS, randomized, placebo-controlled presenting
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
